GeoVax Labs Inc
NASDAQ:GOVX
GeoVax Labs Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. The company is headquartered in Smyrna, Georgia. The firm is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The firm is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. The company is headquartered in Smyrna, Georgia. The firm is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The firm is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
Revenue Decline: GeoVax reported $2.5 million in revenue for the first nine months of 2025, down from $3.1 million in the same period last year due to the early termination of the BARDA Project NextGen contract.
Reduced R&D Spending: Research and development expenses decreased to $5 million for the quarter, reflecting lower costs for the terminated BARDA contract and ongoing trials.
Pipeline Progress: The company highlighted advancements in its key programs, especially GEO-MVA (Mpox/Smallpox vaccine), GEO-CM04S1 (COVID-19 for immunocompromised), and Gedeptin (oncology), with new regulatory and collaboration milestones.
EMA Fast Track: GEO-MVA received guidance from the European Medicines Agency allowing it to bypass Phase I and II and move to a Phase III trial, accelerating potential commercialization.
Collaboration Interest: Management noted increased engagement with industry partners and funding organizations for both vaccine and oncology products.
Cash Position: Cash at September 30, 2025, was $5 million, down from $5.5 million at year-end, with ongoing efforts to secure additional funding and partnerships.
